Jinming Yu, MD, PhD, Shandong Cancer Hospital & Institute, Jinan, China Dr. Jinming Yu is the president of Shandong Cancer Hospital & Institute and Chairman designate of Chinese Society of Clinical Oncology. In 2011, he was elected as an academician of the Chinese Academy of Engineering. In 2015, he won Ho Leung Ho Lee Science and Technology Progress Award. He has obtained multiple major research projects, including the National "863" Program, the National "Tenth Five-Year Plan", the National "Eleventh Five-Year Plan", the National "Twelfth Five-Year Plan", and the National Natural Science Foundation. The research achievements have modified the clinical guidelines and protocols of multiple countries, including the United States, Europe, Canada, and China. Dr. Yu has been invited to give academic lectures at internationally renowned universities and medical institutions, such as Stanford University in the United States. He has published over 600 original articles and reviews on many aspects of cancers. His main research fields are the combination of radiotherapy and immunotherapy or targeted therapy, personalized drug design and therapy. |
Shuanghu Yuan, MD, PhD, Shandong Cancer Hospital & Institute, China Dr. Yuan holds the position of chairman at the Chinese Radiation Therapy Oncology Group (CRTOG) and serves as the chief of the Thoracic Radiation Oncology Department of Shandong Cancer Hospital & Institute in China. He secured the research fellow position in Radiation Oncology Department of University of Michigan under the guidance of Feng-Ming Spring Kong. He focuses his research on the interactions between radiotherapy and antitumour immunity, functional image-guided target volume delineation in lung and esophageal cancers, functional imaging and molecular markers-guided adaptive radiation therapy in brain and thoracic cancer, and predictive assays for radiation tumor sensitivity and toxicity. His research has been showcased on several occasions as oral or poster presentations at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the Radiological Society of North America (RSNA), and the Society of Nuclear Medicine Annual Meeting (SNMMI). He has made significant contributions to the field of radiation oncology by publishing over 100 papers and providing valuable insights. In 2015, he received the only International Abstract Award at the 57th Annual Meeting of ASTRO. He was also honored with the Chinese Medical Science Prize in 2016. Additionally, he holds the titles Mountain Tai Scholar of Shandong Province and State Council Special Allowance Specialist. He has been the recipient of numerous research grants, including the National Key Research and Development Program of China, the National High Technology Research and Development Program of China (863 Program), and the National Natural Science Foundation of China. |
Jing Cai, Ph.D., Fellow of AAPM, The Hong Kong Polytechnic University, China Prof. Jing CAI is a tenured full professor of The Hong Kong Polytechnic University, Associate Dean of the Faculty of Health and Social Sciences, and Fellow of American Association of Physicists in Medicine (AAPM). Prof. Cai earned his PhD in Engineering Physics in 2006 and then completed his clinical residency in Medical Physics in 2009 from the University of Virginia, USA. He joined Duke University as Assistant Professor in 2009, and was promoted to Associate Professor in 2014. He joined The Hong Kong Polytechnic University in 2017, and became the funding Director of Medical Physics in 2020. He is the PI/Co-PI for more than 40 external research funds, with a total funding amount of more than 100M HK Dollars. He has published over 170 journal papers and 300 conference papers/proceedings, and has mentored over 100 trainees (PhD, Postdoc, MPhil, MSc, etc.) as the supervisor. He serves on the editorial boards for several prestigious journals in the fields of medical physics and radiation oncology. Prof. Cai is the funding President of The Federation of Medical Imaging and Radiation Therapeutics in Asia (FMIRTIA). |
Renaud de Crevoisier, M.D., Ph.D., Centre Eugène Marquis, France Renaud de Crevoisier is a university professor and hospital practitioner (radiotherapist). He worked for 10 years at the Gustave-Roussy Institute in Villejuit. He conducted a two-year research activity in the United States on prostate cancer. He specializes in the treatment of urological cancers (prostate) and innovative techniques. He is also co-responsible for an INSERM 642 / LTSI (signal and image Processing Laboratory) team aimed at improving tumour targeting. He was authorized to lead Research (HDR) of high-precision radiotherapy in University of Rennes since 2007. He was elected as the President of the Scientific Council of the Société française de radiotherapy Oncologie (SFRO) in 2010. He served as the member of the Scientific Council of the SFRO and the Scientific Council of the European Society for therapeutic Radiation and Oncology (GEC-ESTRO). He is also the member of editorial board of the journal Cancer Radiotherapie and the reviewer of several national and international journals. |
Fada Guan, Ph.D., Yale University School of Medicine, USA Dr. Fada Guan obtained his bachelor’s degree from Tsinghua University in China and his M.S. and Ph.D. degrees from Texas A&M University in the USA. He used to be an Assistant Professor in the Department of Radiation Physics at The University of Texas MD Anderson Cancer Center. He is currently working at Yale School of Medicine/Yale New Haven Hospital as an Assistant Professor and medical physicist. He has extensive experience in the application of Monte Carlo techniques in the field of medical radiation physics and radiation biology. He is a member of the Electromagnetic Physics Working Group of Geant4 Monte Carlo Simulation International Collaboration. He is a member of the Joint Working Group for Research Seed Funding Initiative (JWGRSF) of the American Association of Physicists in Medicine. He is a development team member of the open-source medical physics Python library—PyMedPhys. He serves as an associate editor or editorial board member of different international journals in radiation oncology physics. His primary research areas include the physical characteristics and biological effects of proton and heavy-ion radiotherapy, microdosimetry, and X-ray Bragg diffraction. |
Zhongxing Liao, M.D., The University of Texas MD Anderson Cancer Center, USA Dr. Zhongxing Liao is a tenured Professor of Radiation Oncology with the Elza A. and Ina Shackelford Freeman Endowed Professorship in Lung Cancer, at the University of Texas MD Anderson Cancer Center, Houston, Texas. She graduated from Xiangya Medical School, Hunan, China and received her post doctorate training at the Experimental Radiation Oncology, and Clinical Resident Training at Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center. She has a broad background in thoracic radiation oncology, with specific expertise in prospective comparative clinical trials, predictive model using radiation dosimetric metrics and biomarker. She has pioneered in implementing advanced radiation delivery technologies to enhance the therapeutic ratio by significantly reduce lung toxicity. Her seminal research work that highly impacted patient care includes demonstrating volume effect in radiation induced lung injury in vivo and in human, demonstrating the improved outcome by using advanced radiation technology for lung cancer patients, and being the first to complete a prospective randomized trial comparing proton with photon radiation for patients with NSCLC. She is the national PI for a phase III prospective randomized trial of proton and photons for lung cancer. She currently serves as the Department Chair ad interim of Thoracic Radiation Oncology, Director and Vice Chair of Clinical Research of Radiation Oncology, Division of Radiation Oncology at University of Texas MD Anderson Cancer Center, and Director of Thoracic Service line. She also served as the president of American Association of Woman Radiologists (AAWR), International Education Committee of American Society for Therapeutic Radiology and Oncology (ASTRO), and member of executive committee for lung cancer at NRG. She is a fellow of ASTRO and fellow of AAWR. She has won many awards including Provost's Distinguished Faculty Mentoring Awards Nominee, President's Recognition of Faculty Excellence, Gold Medal Award of G. H. Fletcher Society, and the 2021 Samuel J. Hassenbusch, III, Leadership & Institutional Service award, the Marie Sklodowska-Curie Award-AAWR, American College of Radiology and American Medical Association, and the Outstanding International Collaboration Award from CSTRO. |
Jun Yang, PhD, Foshan Chancheng Hospital, USA Dr. Jun Yang received his PhD in medial physics and medical imaging processing from Bio-medical Engineering, University of Miami in 2006. He has founded of Philadelphia Cyberknife in 2006, the first Cyberknife Center in great Philadelphia area. He served as the chief physicist for Delaware County Hospital and Alliance Oncology (The third largest radiation oncology chain and the largest radiosurgery chain in the states) where he was in charge of the physics, clinical research etc. He found JunXin Oncology Group in China to setup a chain of high standard oncology services in China and serves as the director of cancer programs in Foshan Chancheng hospital. |
F. Charles Brunicardi, UCLA, Los Angeles, CA, USA
Ling Chen, Chinese PLA General Hospital, Beijing, China
Danny Dhanasekaran, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Zhen Fan, UT MD Anderson Cancer Center, Houston, TX, USA
Xianshu Gao, Peking University First Hospital, Beijing, China
Pengfei Ge, Jilin University, Changchun, China
Xishan Hao, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Liuyan (Jennifer) Jiang, Mayo Clinic, Phoenix, AZ, USA
Tao Jiang, Capital Medical University, Beijing, China
Jing Jin, The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Chunsheng Kang, Tianjin Medical University, Tianjin, China
X Allen Li, Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
Yulan Liang, University of Maryland, Baltimore, MD, USA
Xiongbin Lu, UT MD Anderson Cancer Center, Houston, TX, USA
Liang Qiao, The University of Sydney, Sydney, Australia
Zhimin Shao, Fudan University Shanghai Cancer Center, Shanghai, China
Qiang Shen, UT MD Anderson Cancer Center, Houston, TX, USA
Zhiyuan Shen, Rutgers University, New Brunswick, NJ, USA
Dian Wang, Rush University (Chicago), Chicago, IL, USA
Fen Wang, University of Kansas Medical Center, Kansas City, KS, USA
Jenny Wang, Eppley Institute for Research in Cancer, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
Junjie Wang, Peking University International Hospital, Beijing, China
Xiuying Wang, The University of Sydney, Sydney, Australia
Ya Wang, Emory University, Atlanta, GA, USA
Lei Xing, Stanford University, Stanford, CA, USA
Binghe Xu, The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Liang Xu, Department of Molecular Biosciences, College of Liberal Arts and Sciences, University of Kansas, Lawrence, KS, USA
Jianhua Yang, Baylor College of Medicine, Houston, TX, USA
Jingxuan Yang, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Qifeng Yang, Qilu Hospital of Shandong University, Jinan, China
Junlin Yi, The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Ning J. Yue, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Fuquan Zhang, Peking Union Medical College Hospital, Beijing, China
Huojun Zhang, Changhai Hospital, Shanghai, China
Shengtao Zhou, Sichuan University, Chengdu, China
Jun Ma
Shandong Cancer Hospital & Institute, Jinan, China
cjcptmj@126.com
China
Mingsong Liu received his B.A. (Hons) from Queen's University in Kingston, Ontario, Canada, with major in Linguistics. He worked as a copywriting intern in Vancouver, Canada, and after graduation he joined Wiley as a Journal Publishing Assistant. At present, he is supporting Journal Publishing Managers in the Health Sciences team and its journal portfolio. |